"Pharmaceutical Speed Reading Society" Yan Jian and Denali cooperation Novarx Xolair new adaptive disorders approved by the European Union.

August 7, 2020 / Medical Information List: $1 billion to help Parkinson's disease therapy development Yan Jian and Denili reached a partnership; Tecentriq combined with yew alcohol first-line treatment of tri-negative breast cancer Phase III clinical failure; Lingbei terminated a new drug for schizophrenia Phase 2 clinical research; the U.S. FDA granted strong de-adrenaline reuptake inhibitor AXS-12 breakthrough drug eligibility ... Daily fresh medicine news, quick reading with you to pay attention to! Part 1 Policy Brief August 6 27 new confirmed local cases nationwide August 6 from 0 to 24 hours, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang Production and Construction Corps reported 37 new confirmed cases, of which 1 case was imported from abroad 0 cases (7 in Shanghai, 1 in Liaoning, 1 in Jiangsu, 1 in Sichuan), 27 local cases (26 in Xinjiang, 1 in Beijing), no new deaths, 2 new suspected cases, all imported from abroad (all in Shanghai).
(National Health And Health Commission) 10 provinces supplies belt purchase price information published 6, Shaanxi Province Public Resources Trading Center issued "on the inter-provincial alliance of public medical institutions artificial crystal cross-regional joint belt volume procurement bargaining matters notice", the public belt volume procurement products group and the corresponding declared prices of arms enterprises.
notice, the bargaining time is from 9 a.m. on August 15, 2020.
National public medical institutions in Ningxia, Gansu, Qinghai, Xinjiang, Xinjiang Construction Corps, Hunan, Guangxi, Guizhou, Hainan and Shaanxi provinces (regions, corps) and secondary public medical institutions with artificial crystal-related surgery will participate in this joint volume procurement.
(Public Resources Trading Center of Shaanxi Province) Part 2 has been observed Tyger Pharmaceuticals landing on the Hong Kong Stock Exchange Tag Pharmaceuticals officially listed on the Hong Kong Stock Exchange, becoming the third "A-H" CRO enterprises in China.
the offering, priced at HK$100/share and opening at HK$119/share, was the largest IPOs by Asian biopharmaceutical companies since 2020 with a HK$10.3bn capital raising.
(Shell Society) $1 billion to help Parkinson's Disease Therapy Development Yan Jian and Denali reached a partnership between Yan Jian and Denali announced that the two sides have reached an agreement to jointly develop and promote Denali's LRRK2 small molecule inhibitor DNL151 for the treatment of Parkinson's disease.
will make an upfront payment of $560 million to Denali and a $465 million equity investment in Denali.
Denali is also eligible for a potential milestone payment of up to $1.125 billion.
(Pharmaceutical Mingkangde) Shanghai Pharma won the exclusive interest of Yino Micro pharma next-generation lysoma virus therapy in Greater China on the 6th, also Noo Micro pharma and Shanghai Pharmaceutical jointly announced the signing of a licensing agreement, Shanghai Pharmaceuticals obtained the former soluble virus MVR-T3011 in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan) exclusive clinical development and commercial rights.
micropharmaceuticals retains the development and commercialization interests of MVR-T3011 outside greater China.
(Pharmaceutical Mission Hills) Yichen Pharmaceuticals completed 20 million U.S. dollars A-plus round financing Xenchen Pharmaceuticals announced that the company recently completed 20 million U.S. dollars A-plus round financing.
This round of financing will be used to accelerate the clinical research of AAM-1310 in Xenopha and the development of several existing preclinical projects, further enrich the research and development pipeline, and create sustainable value in the development of small molecules that can break through the blood-brain barrier.
a $20 million investment in GentiBio, a new Tregs cell therapy developed by Pharmaceutical Mission, announced the completion of a $20 million seed round financing.
The current round of funding, led by OrbiMed, Novartis Venture Fund and RA Capital Management, will be used for gentiBio's development of engineered regulatory T cells to provide new immunotherapy for autoimmune, immune and allergic diseases.
(Pharmaceutical Rubik's Cube) Caprion-HistoGeneX and Viroclinics-DDL announced a strategic partnership between Caprion-HistoGeneX and Viroclinics-DDL to expand their global capabilities to meet the needs of infectious diseases such as emerging coronary pneumonia.
the partnership brings together the leadership of two leading contract research organizations that provide specialized testing analysis and technology related to clinical and preclinical research aimed at developing infectious disease vaccines and other therapies for the pharmaceutical and biotechnology industries.
teladoc's $18.5bn acquisition of Livongo, which it bought for $18.5bn.
$18.5 billion, making it the third-largest acquisition of a U.S. company this year.
under the terms of the agreement, Teladoc paid $11.33 per share for Livongo shares and exchanged 0.592 Teladoc shares for livongo Health shares, which is equivalent to a 58 per cent to 42 per cent split in control.
(Eugene Health Official) Part 3 Drug News Tecentriq joint first-line treatment of three-negative breast cancer Phase III clinical failure local time 6, Roche published PD-L1 inhibitor Tecentriq and yew alcohol co-use, first-line treatment of PD-L1 positive metastatic tricycosis breast cancer patients in phase 3 clinical study Ofassion 131 data.
results showed that the study did not reach the main endpoint, and that the improvement in non-progressive survival of tecentriq and yew alcohol group was not statistically significant compared to yew alcohol and placebo.
, the total lifetime data of secondary endpoints also showed a negative trend.
(Sina Pharmaceutical News) Lingbei terminated the Phase 2 clinical study of a new drug for schizophrenia, Lingbei announced the discontinuation of the Lu AF11167 Phase II proof-of-concept clinical study for patients with schizophrenia with persistent negative symptoms.
This decision is based on the results of a mid-term analysis that concluded that the trial was unlikely to achieve statistically significant statistically significant changes at its main endpoint, namely, the average change in the concise negative symptom scale from baseline examination to week 12 patients.
results of RNAi therapy positive Dicerna released the results of Phase 1 clinical trial of RNAi therapy RG6346 for chronic hepatitis B.
showed that RG6346 was able to further reduce the level of hepatitis B surface antigen levels in the blood of chronic hepatitis B patients who had received antiviral therapy by a further 1.8 exponential levels, and showed long-term efficacy in some patients.
(Drug Mingkangde) Novartis anti-inflammatory drug Xolair new adaptive disease approved by the European Union recently, Novartis announced that the European Union has approved the anti-inflammatory drug Xolair a new adaptation, as an additional treatment for the nasal corticosteroids (INC) for the treatment of severe chronic sinusitis with NASP polyps (CRSwNP) adult patients (18 years old).
Phase III study showed that Xolair reduced the size of nasal pups and improved symptoms and quality of life in CRSwNP patients.
(Bio Valley) The U.S. FDA has granted AXS-12, a breakthrough drug for the powerful adrenaline reuptake inhibitor AXS-12, the FDA has granted AXS-12 a breakthrough drug for the treatment of sudden collapse in patients with onset sleeping sickness.
AXS-12 is a new, oral, highly selective, powerful epinephrine reuptake inhibitor, which is about to enter Phase III clinical development for the treatment of onset sleeping sickness.
(Bio Valley) Eddie Pharmaceuticals' first NDA to be included in the priority review CDE website information shows that Eddie Pharmaceuticals' application for the listing of ACC007, a new class of AIDS candidate drug, was included in the proposed priority review list on August 6.
noteworthy that ACC007's listing application was accepted by CDE just over a week ago, the first new drug listing application (NDA) submitted by Eddy Pharmaceuticals.
(CDE)